Tumor Heterogeneity-Driven Individualized Therapy

Future OncologyVol. 17, No. 3 CommentaryTumor heterogeneity-driven individualized therapyEvangelos G Baltagiannis, Demosthenis E Ziogas, William C Cho, Michail Mitsis & Dimitrios H RoukosEvangelos G BaltagiannisCentre for Biosystems & Genome Network Medicine, Ioannina University, Ioannina, 45110, GreeceDepartment of Surgery, University Hospital of Ioannina, Ioannina, 45500, Greece, Demosthenis E ZiogasCentre for Biosystems & Genome Network Medicine, Ioannina University, Ioannina, 45110, GreeceDepartment of Surgery, General Hospital of Ioannina, Ioannina, 45445, Greece, William C Cho https://orcid.org/0000-0003-4174-4586Department of Clinical Oncology, Queen Elizabeth Hospital, Kowloon, Hong Kong, 999077, China, Michail MitsisDepartment of Surgery, University Hospital of Ioannina, Ioannina, 45500, GreeceCancer Biobank Centre, Ioannina University, Ioannina, 45110, Greece & Dimitrios H Roukos *Author for correspondence: Tel.: +30 265 100 5572; E-mail Address: droukos@uoi.grhttps://orcid.org/0000-0002-6210-5065Centre for Biosystems & Genome Network Medicine, Ioannina University, Ioannina, 45110, GreeceDepartment of Surgery, University Hospital of Ioannina, Ioannina, 45500, GreeceDepartment of Systems Biology, Biomedical Research Foundation of the Academy of Athens, Athens, 11527, GreecePublished Online:11 Dec 2020https://doi.org/10.2217/fon-2020-0915AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: combination therapyintratumor variabilityliquid biopsy next-generation sequencingpredictive biomarkerReferences1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J. Clin. 70(1), 7–30 (2020).Crossref, Medline, Google Scholar2. NCCN. Evidence-based cancer guidelines, oncology drug compendium, oncology continuing medical education. www.nccn.org/Google Scholar3. IARC. Latest world cancer statistics – GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. https://www.iarc.fr/news-events/latest-world-cancer-statistics-globocan-2012-estimated-cancer-incidence-mortality-and-prevalence-worldwide-in-2012/Google Scholar4. Campbell PJ, Getz G, Korbel JO et al. Pan-cancer analysis of whole genomes. Nature 578(7793), 82–93 (2020).Crossref, Medline, Google Scholar5. Hellmann MD, Ciuleanu TE, Pluzanski A et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N. Engl J. Med. 378(22), 2093–2104 (2018).Crossref, Medline, CAS, Google Scholar6. Ben-David U, Siranosian B, Ha G et al. Genetic and transcriptional evolution alters cancer cell line drug response. Nature 560(7718), 325–330 (2018).Crossref, Medline, CAS, Google Scholar7. AbdulJabbar K, Raza SEA, Rosenthal R et al. Geospatial immune variability illuminates differential evolution of lung adenocarcinoma. Nat. Med. 26(7), 1054–1062 (2020).Crossref, Medline, CAS, Google Scholar8. Kilgour E, Rothwell DG, Brady G, Dive C. Liquid biopsy-based biomarkers of treatment response and resistance. Cancer Cell 37(4), 485–495 (2020).Crossref, Medline, CAS, Google Scholar9. Sabarinathan R, Pich O, Martincorena I et al. The whole-genome panorama of cancer drivers. bioRxiv (2017).Google Scholar10. Murciano-Goroff YR, Taylor BS, Hyman DM, Schram AM. Toward a more precise future for oncology. Cancer Cell 37(4), 431–442 (2020).Crossref, Medline, CAS, Google Scholar11. Alexandrov LB, Kim J, Haradhvala NJ et al. The repertoire of mutational signatures in human cancer. Nature 578(7793), 94–101 (2020).Crossref, Medline, CAS, Google Scholar12. Calabrese C, Davidson NR, Demircioğlu D et al. Genomic basis for RNA alterations in cancer. Nature 578(7793), 129–136 (2020).Crossref, Medline, CAS, Google Scholar13. Lim B, Lin Y, Navin N. Advancing cancer research and medicine with single-cell genomics. Cancer Cell 37(4), 456–470 (2020).Crossref, Medline, CAS, Google Scholar14. Pishvaian MJ, Blais EM, Brody JR et al. Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial. Lancet Oncol. 21(4), 508–518 (2020).Crossref, Medline, CAS, Google Scholar15. Paz-Ares L, Luft A, Vicente D et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 379(29), 2040–2051 (2018).Crossref, Medline, CAS, Google Scholar16. Forde PM, Chaft JE, Smith KN et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N. Engl J. Med. 378(21), 1976–1986 (2018).Crossref, Medline, CAS, Google Scholar17. Porteus MH. A new class of medicines through DNA editing. N. Engl J. Med. 380(10), 947–959 (2019).Crossref, Medline, CAS, Google Scholar18. Rodon J et al. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nat. Med. 25, 751–758 (2019).Crossref, Medline, CAS, Google Scholar19. Jamal-Hanjani M et al. Tracking the evolution of non-small-cell lung cancer. N. Engl. J. Med. 376, 2109–2121 (2017).Crossref, Medline, CAS, Google Scholar20. Liu MC, Oxnard GR, Klein EA et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann. Oncol. 31(6), 745–759 (2020).Crossref, Medline, CAS, Google Scholar21. Cristiano S, Leal A, Phallen J et al. Genome-wide cell-free DNA fragmentation in patients with cancer. Nature 570, 385–389 (2019).Crossref, Medline, CAS, Google Scholar22. Zviran A et al. Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. Nat. Med. 26, 1114–1124 (2020).Crossref, Medline, CAS, Google Scholar23. Roukos DH. Spatiotemporal diversification of intrapatient genomic clones and early drug development concepts realize the roadmap of precision cancer medicine. Drug Discov. Today 22(8), 1148–1164 (2017).Crossref, Medline, Google Scholar24. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW. Cancer genome landscapes. Science 339(6127), 1546–1558 (2013).Crossref, Medline, CAS, Google Scholar25. Iacobuzio-Donahue CA, Litchfield K, Swanton C. Intratumor heterogeneity reflects clinical disease course. Nat. Cancer 1(1), 3–6 (2020).Crossref, Google Scholar26. Rozenblatt-Rosen O, Regev A, Oberdoerffer P et al. The Human Tumor Atlas Network: charting tumor transitions across space and time at single-cell resolution. Cell 181(2), 236–249 (2020).Crossref, Medline, CAS, Google Scholar27. Costanzo M, Kuzmin E, van Leeuwen J et al. Global genetic networks and the genotype-to-phenotype relationship. Cell 177(1), 85–100 (2019).Crossref, Medline, CAS, Google Scholar28. Califano A, Alvarez MJ. The recurrent architecture of tumour initiation, progression and drug sensitivity. Nat. Rev. Cancer 17(2), 116–130 (2017).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByTouch Imprint Intraoperative Flow Cytometry as a Complementary Tool for Detailed Assessment of Resection Margins and Tumor Biology in Liver Surgery for Primary and Metastatic Liver Neoplasms15 September 2021 | Methods and Protocols, Vol. 4, No. 3 Vol. 17, No. 3 eToC Sign up Follow us on social media for the latest updates Metrics Downloaded 123 times History Received 6 September 2020 Accepted 29 September 2020 Published online 11 December 2020 Published in print January 2021 Information© 2020 Future Medicine LtdKeywordscombination therapyintratumor variabilityliquid biopsy next-generation sequencingpredictive biomarkerFinancial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents, received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download